Læknablaðið : fylgirit - 01.08.2003, Page 66

I POSTERS / 27TH NORDIC PSYCHIATRIC CONGRESS
Week 8 (OC) was 64% and 52%, respectively; escitalopram was
superior to both citalopram and placebo with respect to these
parameters. Secondary efficacy analyses using the CGI-S and CGI-
I scales showed a significant superior effect (p<0.05) for escitalo-
pram versus placebo as early as Week 1 on each scale. This effect
was sustained through to Week 8.
Escitalopram was very well tolerated, with an adverse event pro-
file that was as favourable as that for citalopram. The withdrawal
rate was 10% for the placebo group, 6% for the escitalopram group,
and 5% for the citalopram group. The withdrawal rate due to ad-
verse events for the escitalopram group (2.6%) was identical to the
placebo group.
P - 24 Thursday 14/8,14:00-15:00
Thought suppression in smoking dependency
Jón T. Ingjaldsson Dr., Researcher, Psychologist, Norwegian Department of Defen-
sive Leadership, Akershus Festning, 0015 Oslo Mil, Norway. Smári J, Laberg JC,
Thayer JF.
Jon. Ingjaldsson@psych. uib. no
Purpose: The aim of the current study was to investigate the effect
of thought suppression on the frequency of smoking related thoughts
in smokers.
Method: A total of 407 individuals labelled as active smokers, quit-
ters and non smokers were either instructed to suppress or not to
suppress their thoughts of smoking after exposure to smoking re-
lated or non-smoking related videotape in a controlled experiment.
Self-reported frequency of thoughts of smoking was registered on
baseline, after manipulation (exposure and instruction) and at
follow up.
Kesults: Active smokers reported in general more frequent smo-
king related thoughts and slower habituation of such thoughts com-
pared to non-smokers and quitters. Importantly, active smokers had
problems with effectively suppressing smoking related thoughts
after exposure to smoking related videotape, while suppression re-
duced thoughts on smoking in other active smokers exposed to
neutral cues. Frequency of thoughts of smoking in active smokers
was positively related to urge to smoke, worry and negative affect.
Implication: Instructed thought suppression is useful method for
investigating involuntary cognition in addiction. To successfully
cope with high risk situations more flexible mental strategies are
advised.
P - 25 Thursday 14/8,14:00-15:00
Quetiapine for the treatment of mania in bipolar disorder:
A randomized controlled trial
Björn Paulsson, MD, Associate Director, Dept. of Biostatistics, Astra Zeneca,
Clinical R&D Södertálje (B238) S-151 85, Södertálje. Huizar K.
bjorn.paulsson @astrazeneca. com
Background: Monotherapy with lithium or an atypical antipsycho-
tic is recommended therapy for treatment of mania.
Aims: Evaluate quetiapine as monotherapy for mania.
Methods: 302 patients (bipolar I disorder, manic episode) were ran-
domized to 12 weeks double-blind treatment with quetiapine
(QTP) (flexibly dosed up to 800 mg/d), placebo (PBO), or lithium
(0.6-1.4 mEq/L).
Results: 67.3% (72/107) of QTP-, 36.1% (35/97) PBO-, and 68.4%
(67/98) lithium-treated patients completed the trial. Quetiapine-
treated patients had a significantly greater reduction in mean
YMRS scores vs PBO at Day 21 (-14.62 vs -6.71; P<0.0001) and
Day 84 (P<0.0001). Significantly more QTP palients achieved a
response (>50% decrease from baseline YMRS score) at Day 21
(QTP 53.3%; PBO 27.4%; P=0.0002), and Day 84 (QTP 72%; PBO
41.1%; P<0.0001). Quetiapine and lithium were similar in all effi-
cacy measures vs PBO. Most common adverse events (>10%) in
QTP-treated patients included dry mouth and somnolence. Lithi-
um was associated with tremor. Mean last-week QTP dose in re-
sponders at Day 21 was 586 mg/d.
Conclusions: In acute mania, quetiapine monotherapy is well
tolerated and significantly more effective than placebo.
P - 26 Thursday 14/8,14:00-15:00
Quetiapine adjunctive therapy for acute mania associated
with bipolar disorder
Jamie Mullen, MD. Director, Clinical Research, AstraZeneca, 1800 Concord Pike,
FOC-2, RO. Box 15437 Wilmington, DE 19850, USA. Nancy Devine, MS, Dennis
Sweitzer, PhD.
jamie. mullen @astrazeneca. com
Background: The addition of an atypical antipsychotic to lithium or
divalproex is a first-line option for the treatment of more severe
and psychotic forms of mania, although few clinical studies have
been undertaken to support this approach.
Aims: Evaluate quetiapine (QTP) in combination with lithium (Li)
or divalproex (DVP) for the treatment of mania.
Methods: Subjects with bipolar I mania were randomized to 21 days
double-blind treatment with: QTP (flexibly dosed up to 800 mg/d)
plus Li or DVP (target trough serum concentrations 0.7-1.0 mEq/L
and 50-100 pg/mL, respectively); or placebo (PBO) plus Li/DVP.
Results: 56/91 (61.5%) QTP+Li/DVP-treated patients completed,
compared to 49/100 (49.0%) in the PBO+Li/DVP group. By Day 21
QTP+Li/DVP-treated patients had a significantly greater reduction
in YMRS compared with the PBO+Li/DVP group (-211;13.76 vs -
;9.93; P=0.021). Significantly more quetiapine-treated patients (54.3%)
achieved a YMRS response at Day 21 than Li/DVP-treated
patients (32.6%) (P=0.005). Mean last-week quetiapine dose in
responders was 580 mg/d. Common adverse events (>;10%) inclu-
ded somnolence, dry mouth, asthenia, and postural hypotension.
Discontinuation due to adverse events was similar in both groups.
Condusions: Quetiapine in combination with lithium or divalproex
is well tolerated and has superior efficacy in acute mania compared
to Li/DVP alone.
P - 27 Thursday 14/8,14:00-15:00
Possible mechanisms of antipsychotic-induced long-term
weight gain
Marc Zicgcnbcin. MD. Social Psychiatry and Psychotherapy, Medical School
66 LÆKNABLAÐIÐ / FYLGIRIT 48 2003/89